Ramsay sedation scale, respiratory and hemodynamic parameters, P/F ratio were evaluated at baseline.
The intensity and frequency were evaluated at baseline and at two-year follow-up.
Clinical symptoms, electrolytes, and acid-base status were evaluated at baseline and after 4 h.
Metabolic markers were evaluated at baseline and at the end of the study.
Antibody levels to 11 Pn strains were evaluated at baseline and 1-month.
Participants were evaluated at baseline and at 6-month intervals with standardized interview instruments.
Subjects were evaluated at baseline, 3 months, 6 months and a follow up visit at 9 months.
Clinical and neurohumoral status were evaluated at baseline, on chronic therapy at the target dose, and during cessation of therapy.
Results: Subjects were evaluated at baseline and 2 weeks later using measures of depression, apathy, and cognitive impairment.
Fasting lipoprotein and lipid measurements were evaluated at baseline and at 8-week intervals during the Reference and MUFA diets.
Main Outcome Measures: Outcome measures were evaluated at baseline and at 1, 2, 3, and 6 months.
